Evidence map›Paper›PMID 41708533›Full record

Observational studyAllergy2026

Small Airways Dysfunction and Remission in Adults With Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study.

Akshi Kumar, Rory Chan, Nazanin Zounemat-Kermani, Eleanor Quek, Ian M Adcock, Bianca Beghe, Christopher Brightling, Dave Singh, Janwillem Kocks, Alberto Papi and 5 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02123667 (AssessmenT of smalL Airways involvemeNT In aSthma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02123667 completednot on this map

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.

TypeobservationalSponsorChiesi Farmaceutici S.p.A.Ran2014 to 2017Enrolled872ConditionsAsthma
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. From FEVJournal of asthma and allergy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akshi KumarNational Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.
Rory ChanSchool of Medicine, University of Dundee, Dundee, UK.ORCID https://orcid.org/0000-0003-2805-8266
Nazanin Zounemat-KermaniNational Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.
Eleanor QuekNational Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.
Ian M AdcockNational Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-2101-8843
Bianca BegheRespiratory Unit, Hospital Policlinico Modena, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Christopher BrightlingInstitute for Lung Health, National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK.
Dave SinghCentre for Respiratory Medicine and Allergy, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Janwillem KocksGeneral Practitioners Research Institute, Groningen, the Netherlands.
Alberto PapiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Klaus F RabeLungenClinic Grosshansdorf, Grosshansdorf, Germany.ORCID https://orcid.org/0000-0002-7020-1401
Ulrica Scaffidi-ArgentinaGlobal Medical Affairs, Chiesi Farmaceutici S.p.A., Parma, Italy.
Maarten van den BergeDepartment of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Monica KraftDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, New York, USA.
Salman SiddiquiNational Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-3770-7870

Funding

Chiesi Farmaceutici
6 · The paper itself

Abstract

backgroundAsthma remission is a feasible treatment goal. However, remission definitions vary, and predictive biomarkers remain underexplored.

methodsWe conducted a post hoc analysis of ATLANTIS (NCT02123667), a multinational prospective study including 684 adult asthmatics. Remission was defined by 3-component (3C) and 4-component (4C) criteria. 3C remission included: (1) ACQ-6 < 1.5, (2) no maintenance oral corticosteroids, (3) no exacerbations. An absolute decline < 10% in pre-bronchodilator FEV

findingsRemission occurred in 48% (3C) and 45% (4C) of patients. Predictors included male sex, better lung function, fewer previous exacerbations, and higher SADT (fewer small airways symptoms). LDA identified milder disease and was associated with remission [OR 3C 4.43 (2.80, 7.10) and 4C 3.46 (2.23, 5.43)], improved QoL [OR 2.07 (1.65, 2.60)], and fewer future exacerbations [OR 0.43 (0.22, 0.85)]. Transcriptomic analyses revealed remission-associated upregulation of interleukin 4/13 signalling and downregulation of coagulation pathways, in both ATLANTIS and U-BIOPRED.

interpretationSAD was associated with reduced asthma remission. A novel LDA tool demonstrated clinical utility in stratifying prospective asthma risk. Key immunologic and haemostatic pathways may underpin remission, offering potential targets for future intervention.

Indexed as

AsthmaAdultBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesRemission InductionRespiratory Function TestsBiomarkersasthmadisease exacerbationfactor analysisgene expression analysisremission inductionspontaneous remission

Identifiers

PMID41708533
PMCPMC13569693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.